Gossamer Bio FY2030 EPS Forecast Decreased by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – HC Wainwright reduced their FY2030 earnings per share (EPS) estimates for Gossamer Bio in a note issued to investors on Thursday, June 25th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.05 for the year, down from their prior forecast of $0.09. HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.45) per share.

A number of other equities research analysts have also issued reports on GOSS. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Gossamer Bio in a report on Monday, March 23rd. Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Finally, Oppenheimer dropped their target price on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Gossamer Bio currently has an average rating of “Hold” and a consensus price target of $4.50.

Gossamer Bio Trading Down 2.2%

Shares of GOSS opened at $0.17 on Friday. The business’s 50 day moving average is $0.26 and its 200 day moving average is $1.29. Gossamer Bio has a 12-month low of $0.14 and a 12-month high of $3.87. The company has a market capitalization of $38.77 million, a PE ratio of -0.21 and a beta of 2.00.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $16.95 million during the quarter, compared to analyst estimates of $4.67 million.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently bought and sold shares of the business. Tudor Investment Corp ET AL grew its stake in shares of Gossamer Bio by 7.8% in the 3rd quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock worth $132,000 after buying an additional 3,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Gossamer Bio by 24.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,964 shares of the company’s stock worth $74,000 after buying an additional 4,767 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Gossamer Bio by 22.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after buying an additional 4,771 shares in the last quarter. Deutsche Bank AG raised its position in shares of Gossamer Bio by 0.4% during the 4th quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock valued at $3,981,000 after buying an additional 5,414 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV raised its position in shares of Gossamer Bio by 52.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock valued at $74,000 after buying an additional 8,239 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.